Article Sidebar
Published:
Mar 4, 2016Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Inhibition of Corneal Neovascularization by Hydrazinocurcumin
Abstract
Purpose: To investigate the effect of hydrazinocurcumin on a human vascular endothelial growth factor (VEGF)-induced corneal neovascularization in rabbit model.
Methods: Murine corneal neovascularization (CorNV) was induced via two intrastromal implantations of VEGF polymer 2 mm from the limbus. Hydrazinocurcumin was administered topically on the cornea 4 times daily for 7 days. The therapeutic effects of hydrazinocurcumin were evaluated daily using slitlamp. At the end of the treatment, the corneas were harvested for H&E staining, masson trichrome staining, immuno-histochemical study, and semi quantification reverse transcription polymerase chain reaction (RT-PCR) was utilized for measurement of inflammation-related molecules.
Results: Topical application of hydrazinocurcumin had significant therapeutic effects on CorNV Hydrazinocurcumin extract treatment was more effective in suppressing CorNV in terms of vessel length and levels of cluster of differentiation 31 (CD31) proteins or angiogenesis-related genes such as VEGF, matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9). The average length of vessels in hydrazinocurcumin-treated group was only 17 % of that in the control group. Hydrazinocurcumin also inhibited inflammation more markedly by more effectively inhibiting mononuclear and polymorphonuclear cell infiltration into the corneal stroma and reducing levels of stromal cell-derived factor-1 (SDF1), tumor necrosis factor-alpha (TNFα) and macrophage inflammatory protein-3 (MIP3a). In addition, the corneas of hydrazinocurcumin group had a more regular and compact architecture of collagen with thinner corneal thickness than those of the untreated group.
Conclusion: Hydrazinocurcumin inhibited human vascular endothelial growth factor (VEGF)-induced rabbit corneal neovascularization and thus can potentially be used for its treatment.
Keywords: Hydrazinocurcumin, Corneal neovascularization, Inflammation, Vascular endothelial growth factor, Corneal thickness
